Shionogi Company Limited

Purdue Pharma L.p.

Kayoko Hata

Laykea Tafesse

Jianming Yu

Moriyasu Masui

Xiaoming Zhou

Bin Shao

Masanao Inagaki

Akira Yukimasa

Hidenori Mikamiyama

Hiroki Yamaguchi

Noriyuki Kurose

Akira Matsumura

Kouki Fuchino

Motohiro Fujiu

Naoko Yamaguchi

Hiroyuki Tobinaga

Kazuya Kano

Kosuke Anan

Kenichiroh Nakamura

Takatsugu Inoue

Manami Masuda

Yasuyoshi Iso

Daisuke Taniyama

Yoshio Hato

Hiromi Nakai

The present invention provides a compound having a TrkA inhibitory activity or a pharmaceutically acceptable salt thereof. The present invention relates to a compound represented by Formula (I): wherein -L- is &#x2014;C(&#x2550;X)&#x2014;, or the like, &#x2014;Z&#x2014; is &#x2014;NR&#x2014;, or the like, &#x2014;Z&#x2014; is &#x2014;NR&#x2014;, or the like, B is substituted or unsubstituted aromatic carbocyclyl, or the like, Y is a single bond, or the like, the ring C is a substituted or unsubstituted aromatic heterocycle, or the like, Ris a hydrogen atom, or the like, and the group represented by is a group represented by Formula: or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.

Heterocycle derivatives having TrkA inhibitory activity

The present invention is related to a compound represented by formula (I), 

Heterocyclic derivative having PGD2 receptor antagonist activity

The invention relates to acrylamide compounds of Formula I mentioned below. The invention is also directed to the use compounds of Formula I to treat or prevent a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain. 

Acrylamide compounds and the use thereof

Growing community of inventors

Osaka, Japan

Kayoko Hata